All Articles

Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

Evolving epidemiology and antimicrobial resistance in cirrhosis: time for a region-specific approach

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management

Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions

Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

Multidisciplinary management of HCC

From algorithm to dialogue: interpreting the 2026 BCLC-CUSE strategy for HCC care

Precision medicine in metabolic dysfunction-associated steatotic liver disease: genetics, epigenetics, and emerging therapies

Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives

Global burden of liver cancer mortality due to alcohol use from 1990 to 2021 and predictions to 2050

Gut microbiota as predictors of immunotherapy response in hepatocellular carcinoma

Hepatocellular carcinoma tumor immune microenvironment: heterogeneity and therapeutic strategies